Search Results

You are looking at 1 - 10 of 112 items for :

  • Refine by Access: All x
Clear All
Full access

Susan M. Domchek, Jill E. Stopfer, and Timothy R. Rebbeck

. References 1. Rebbeck TR Lynch HT Neuhausen SL . Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations . N Engl J Med 2002 ; 346 : 1616 – 1622 . 2. Kauff ND Satagopan JM Robson ME . Risk-reducing salpingo-oophorectomy in

Full access

Caiqian Cropper, Ashley Woodson, Banu Arun, Carlos Barcenas, Jennifer Litton, Sarah Noblin, Diane Liu, Minjeong Park, and Molly Daniels

) associated with germline mutations in the BRCA1 and BRCA2 genes 2 is the most common hereditary breast cancer predisposition. In the general population, approximately 1 in 400 people (possibly up to 1/200 in select populations) have a BRCA1/2 mutation

Full access

Megan Randall, Kelly Burgess, Lela Buckingham, and Lydia Usha

effective in patients with germline mutations in the BRCA1 and BRCA2 genes ( BRCA mutations). 1 Little is known, however, about any correlation between the size and location of the BRCA mutation and response to PARP inhibitors. Genetic testing for

Full access

Jocelyn S. Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles J. Zaloudek, Stefanie Ueda, Eric A. Collisson, and Barry S. Taylor

*, and BRCA2 I605fs*11 ( Figure 2A ). Figure 1 Imaging and pathology reveal ambiguous diagnosis. (A) Coronal CT of the abdomen shows confluent retroperitoneal and porta hepatis lymphadenopathy (top arrows) resulting in moderate obstruction of the

Full access

Mary B. Daly, Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P. Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R. Smith, Elizabeth Swisher, and Jeffrey N. Weitzel

hereditary cancers, advances in molecular genetics have identified several genes associated with inherited susceptibility to breast and/or ovarian cancers (e.g., BRCA1, BRCA2, PTEN, TP53, CDH1 ) and provided a means of characterizing the specific gene

Full access

Eric Lu, George V. Thomas, Yiyi Chen, Alexander W. Wyatt, Paul Lloyd, Jack Youngren, David Quigley, Raymond Bergan, Shawna Bailey, Tomasz M. Beer, Felix Y. Feng, Eric J. Small, and Joshi J. Alumkal

Myriad Genetic Laboratories or the OHSU clinical laboratory for testing. Seven patients underwent somatic testing, performed in accordance with standard operating procedures (patients 1–3, 5–8). 12 Of these patients, 1 had tumor testing for BRCA2 alone

Full access

Huong T. Le-Petross

patients with germline mutations of BRCA1 . Lancet 1998 ; 351 : 316 – 321 . 4. Cancer Research Campaign (CRC) Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, U.K. Cancer risks in BRCA2 mutation carriers . The Breast

Full access

Tomas G. Lyons and Mark E. Robson

significant replication stress. Replication fork stalling occurs with subsequent collapse and the formation of double-strand breaks (DSBs). 4 Homologous recombination–directed repair is a highly accurate process for repairing DSBs. Both BRCA1 and BRCA2

Full access

Yao Zhu, Yu Wei, Hao Zeng, Yonghong Li, Chi-Fai Ng, Fangjian Zhou, Caiyun He, Guangxi Sun, Yuchao Ni, Peter K.F. Chiu, Jeremy Y.C. Teoh, Beihe Wang, Jian Pan, Fangning Wan, Bo Dai, Xiaojian Qin, Guowen Lin, Hualei Gan, Junlong Wu, and Dingwei Ye

, BRCA1 , BRCA2 , CHEK2 , MLH1 , MSH2 , MSH6 , NBN , PALB2 , and PMS2 ) and HOXB13 (G84E) have also been identified to be associated with increased PCa risk in men of European ancestry. 7 , 8 In addition, germline mutations in DRGs were

Full access

Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, and Rashmi Kumar

, advances in molecular genetics have identified several genes associated with inherited susceptibility to breast and/or ovarian cancers (eg, BRCA1, BRCA2, PTEN [phosphatase and tensin homolog], TP53, CDH1 ) and provided a means of characterizing the